| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 7% | $1,243,200 | 4,440,000 | BVF PARTNERS L P/IL | 31 Mar 2025 | |||
| TANG CAPITAL MANAGEMENT LLC | 5% | -50% | $1,183,700 | -$1,112,990 | 3,115,000 | -48% | TANG CAPITAL MANAGEMENT, LLC | 30 Jun 2025 |
| VANGUARD GROUP INC | 4.4% | $730,813 | 2,610,045 | The Vanguard Group | 31 Dec 2024 | |||
| GOLDMAN SACHS GROUP INC | 2.8% | $471,340 | 1,683,356 | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2024 | |||
| BlackRock, Inc. | 0.6% | -96% | $121,786 | -$922,064 | 369,048 | -88% | BlackRock, Inc. | 30 Jun 2025 |
As of 30 Sep 2025, 1 institutional investors reported holding 2,000 shares of Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV). This represents 0% of the company’s total 62,337,402 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 2,000 | $720 | -$10,839,956 | $0.36 | 1 |
| 2025 Q2 | 29,539,373 | $10,842,562 | -$793,399 | $0.37 | 63 |
| 2025 Q1 | 33,845,637 | $8,763,069 | -$4,443,046 | $0.26 | 70 |
| 2024 Q4 | 39,972,031 | $22,485,726 | -$3,751,358 | $0.56 | 70 |
| 2024 Q3 | 45,935,957 | $27,556,394 | -$42,322,025 | $0.60 | 68 |
| 2024 Q2 | 52,117,516 | $140,354,063 | +$17,123,221 | $2.70 | 79 |
| 2024 Q1 | 43,980,695 | $225,620,623 | +$110,247,132 | $5.13 | 61 |
| 2023 Q4 | 25,848,863 | $13,880,951 | -$1,444,457 | $0.54 | 31 |
| 2023 Q3 | 28,047,314 | $18,583,583 | -$4,592,446 | $0.66 | 40 |
| 2023 Q2 | 31,535,984 | $47,935,195 | +$22,145,201 | $1.52 | 37 |
| 2023 Q1 | 16,211,905 | $30,802,606 | +$3,710,820 | $1.90 | 26 |
| 2022 Q4 | 14,422,936 | $13,695,323 | +$98,994 | $0.95 | 25 |
| 2022 Q3 | 14,278,057 | $16,133,000 | -$1,528,405 | $1.13 | 20 |
| 2022 Q2 | 14,967,182 | $20,954,000 | -$7,070,388 | $1.40 | 21 |
| 2022 Q1 | 18,712,066 | $47,157,000 | +$631,496 | $2.52 | 27 |
| 2021 Q4 | 18,302,585 | $110,174,000 | -$3,116,564 | $6.02 | 34 |
| 2021 Q3 | 15,882,998 | $123,294,000 | -$8,121,965 | $7.79 | 21 |
| 2021 Q2 | 16,192,215 | $217,245,000 | +$217,245,015 | $13.57 | 36 |